
==== Front
Brain Behav Immun Health
Brain Behav Immun Health
Brain, Behavior, & Immunity - Health
2666-3546
Elsevier

S2666-3546(24)00121-2
10.1016/j.bbih.2024.100843
100843
Full Length Article
Glycolytic metabolism: Food for immune cells, fuel for depression?
Bekhbat Mandakh mbekhba@emory.edu
⁎
Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA, 30322, USA
⁎ Emory University School of Medicine, 101 Woodruff Cir, Room 4306, Atlanta, GA, 30322, USA. mbekhba@emory.edu
14 8 2024
10 2024
14 8 2024
40 10084317 12 2023
16 7 2024
10 8 2024
© 2024 The Author
2024
https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).
Inflammation is one biological pathway thought to impact the brain to contribute to major depressive disorder (MDD) and is reliably associated with resistance to standard antidepressant treatments. While peripheral immune cells, particularly monocytes, have been associated with aspects of increased inflammation in MDD and symptom severity, significant gaps in knowledge exist regarding the mechanisms by which these cells are activated to contribute to behavioral symptoms in MDD. One concept that has gained recent appreciation is that metabolic rewiring to glycolysis in activated myeloid cells plays a crucial role in facilitating these cells’ pro-inflammatory functions, which may underlie myeloid contribution to systemic inflammation and its effects on the brain. Given emerging evidence from translational studies of depression that peripheral monocytes exhibit signs of glycolytic activation, better understanding the immunometabolic phenotypes of monocytes which are known to be elevated in MDD with high inflammation is a critical step toward comprehending and treating the impact of inflammation on the brain. This narrative review examines the extant literature on glycolytic metabolism of circulating monocytes in depression and discusses the functional implications of immunometabolic shifts at both cellular and systemic levels. Additionally, it proposes potential therapeutic applications of existing immunomodulators that target glycolysis and related metabolic pathways in order to reverse the impact of elevated inflammation on the brain and depressive symptoms.

Keywords

Glycolysis
Inflammation
Monocyte
Depression
Immunometabolism
Glucose
==== Body
pmc1 Introduction

Inflammation is one biological pathway thought to impact the brain to contribute to major depressive disorder (MDD) and is reliably associated with resistance to standard antidepressant treatments (Strawbridge et al., 2015; Haroon et al., 2018a; Chamberlain et al., 2018). Indeed, a subgroup of MDD patients display increased inflammatory cytokines and other biomarkers of inflammation (e.g., C-reactive protein [CRP]) in association with risk factors like stress, trauma, metabolic and sleep disturbances, and aging (Osimo et al., 2019; Raison et al., 2013; Michopoulos et al., 2017; Felger, 2018; Passos et al., 2015). A rich literature has ascribed the impact of inflammation on neurotransmitter systems and neurocircuits that regulate behavioral changes in MDD to circulating inflammatory cytokines and the peripheral blood immune cells that produce them (Felger and Treadway, 2017; Felger et al., 2013a, 2013b, 2015; Yohn et al., 2016; Kitagami et al., 2003; Haroon et al., 2014, 2016, 2018b; Walker et al., 2013; Dantzer and Walker, 2014). While circulating immune cells, particularly monocytes, have been associated with varying aspects of increased inflammation in MDD and symptom severity (Lynall et al., 2019; Bekhbat et al., 2022a), significant gaps in knowledge exist regarding the intracellular mechanisms by which these cells are activated and communicate with the brain to drive behavioral symptoms in MDD.

One concept that has recently gained appreciation in psychoneuroimmunology is that during an immune response, cellular metabolic pathways are dynamically rewired to provide the energy and nutrients required by immune cells to transition into their diverse functional states (Bekhbat et al., 2021, 2022a, 2023; Dantzer et al., 2021; Lucido et al., 2021; Gamradt et al., 2021). Immune cells produce energy (adenosine triphosphate [ATP]) to maintain their cellular functions by breaking down glucose among other nutrients. Under homeostatic/quiescent conditions immune cells metabolize glucose through a two-step process involving glycolysis as a first step which converts glucose to pyruvate in the cytosol. In a second step, pyruvate is further oxidized in the mitochondria through the tricarboxylic acid (TCA) cycle to support oxidative phosphorylation (OXPHOS), a slower biochemical process that generates maximal ATP. However, when faced with pathogens or danger signals that provoke inflammation, immune cells rapidly undergo a metabolic reprogramming (Fig. 1). This response is classically thought to involve an upregulation of glycolysis and a concomitant suppression of mitochondrial OXPHOS, culminating in the diversion of pyruvate towards lactate - a phenomenon first described in tumor cells and cells under hypoxia (Viola et al., 2019). Aerobic glycolysis (that which occurs under normal oxygen conditions) is now understood to meet the functional and energetic demands of activated immune cells. Although a shift to glycolysis substantially cuts down the ATP yield per molecule of glucose, it supplies rapid energy that is pivotal for immediate immune cell activation (Ganeshan and Chawla, 2014). Glycolysis, along with adjacent metabolic pathways like glutaminolysis, also supplies necessary components for swift cellular proliferation or growth, including but not limited to amino acids, nucleotides, and lipids in proliferating cells such as activated T cells (Pearce and Pearce, 2013). As will be summarized in this review, the role of glycolysis extends to supporting the synthesis of host defense factors (Xie et al., 2016; Zhang et al., 2019; Dietl et al., 2010), augmenting phagocytic activity (Pavlou et al., 2017; Michl et al., 1976), as well as promoting cellular motility (Hara et al., 2017; Semba et al., 2016; Kaushik et al., 2019; Cramer et al., 2003) – a suite of functions indispensable for an effective immune response.Fig. 1 Monocyte activation is coupled to metabolic reprograming toward glycolysis which may promote pro-inflammatory functions to contribute to systemic inflammation. Monocytes rely on glucose for energy but metabolize it differently based on their activation status. Naïve monocytes primarily undergo oxidative phosphorylation (OXPHOS) to produce energy, whereas activated monocytes downregulate OXPHOS and shift to glycolysis for faster energy and metabolic intermediates necessary for pro-inflammatory functions such as cytokine production, proliferation, and adherence/migration. Glycolytically activated monocytes may therefore a be contributor to systemic inflammation and immune-to-brain communication, as well as a novel target for immunomodulation approaches in depression.

Fig. 1

It is amply clear that the circulating inflammatory and metabolic disturbances commonly seen in MDD (Chae et al., 2023; Watson et al., 2021; Milaneschi et al., 2020) – in the form of both pathogen- and danger-associated molecular patterns (PAMPs and DAMPs) – can shift immune cells toward glycolytic metabolism, with the clearest evidence in peripheral myeloid cells. In addition to pro-inflammatory stimuli, certain metabolic stress markers, including ATP, insulin, oxidized lipoproteins, and cholesterol crystals, have been shown to induce glycolytic reprogramming in myeloid cells in association with pro-inflammatory processes (O'Rourke et al., 2022; Hu et al., 2020; Ratter et al., 2021; Di Gioia et al., 2020). This is not surprising given that the most important regulators of glycolysis, the phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) signaling pathway and its downstream effector mechanistic target of rapamycin (mTOR), are sensitive to diverse stimuli including growth factors, insulin, glucose, and cytokines (Szwed et al., 2021). One mechanism through which the PI3K/Akt/mTOR axis promotes a feed-forward cycle of glycolysis and inflammation is the transcription factor hypoxia-inducible factor-1α (HIF-1α), which engages in extensive crosstalk with nuclear factor kappa (NFκB) (D'Ignazio et al., 2016) particularly in conditions of immune challenge or inflammatory stimulation, whereas additional pro-glycolytic factors may be involved in conditions of low-grade inflammation.

More than a mere consequence of immune activation, the shift towards myeloid glycolysis and related metabolic changes may in turn actively perpetuate systemic inflammation through increased cytokine and reactive oxygen species production, cell proliferation, and migration, thus contributing to the underlying mechanisms of depression. A better understanding of these intracellular mechanisms is required to develop more nuanced and specific immune-based strategies to reverse the impact of inflammation on the brain and behavior. Here I provide a narrative review of the available studies evaluating glycolytic metabolism of circulating immune cells in MDD with an emphasis on monocytes and discuss the functional role of immunometabolic shifts at cellular and systemic levels. Next, I present possible therapeutic applications of immunometabolic modulators in MDD and suggest future directions in cellular immunometabolic investigations in MDD.

2 Evidence of altered cellular immunometabolism in depression

2.1 Increased glycolysis as a biomarker of depression with high inflammation

A number of gene expression studies in whole blood and peripheral blood mononuclear cells (PBMCs) of depressed patients have highlighted increased glycolysis as a disease biomarker particularly in patients who have elevated inflammation (see Table 1). Blocking inflammation with infliximab has been shown to reduce depressive symptoms in patients with treatment resistant depression and high inflammation, with greatest improvements observed in anhedonia and psychomotor slowing (Raison et al., 2013). Interestingly, those who showed antidepressant response to infliximab had altered baseline expression of glycolysis-related genes, many of which were significantly regulated by infliximab over time compared to non-responders (Mehta et al., 2013). Glycolytic gene expression has also been associated with depressive symptoms that are reliably associated with and known to be induced by circulating inflammation. For example, the severity of psychomotor slowing in medically stable MDD outpatients was associated with gene clusters that were enriched for glycolysis along with inflammatory signaling pathways (e.g., interferon, interleukin [IL]-6) (Bekhbat et al., 2021). Moreover, our previous work has identified links between anhedonia severity in MDD and gene expression patterns related to altered glucose metabolism, such as insulin signaling and the pro-glycolytic HIF-1 pathway, but only among patients with high inflammation (CRP >3 mg/L per CDC/AHA definition of high risk (Pearson et al., 2003)) (Bekhbat et al., 2020). These results suggest that inflammation and altered glucose metabolism synergize at the level of circulating immune cells, thus creating a distinct ‘immunometabolic’ phenotype that promotes depressive symptoms. Interestingly, glycolytic gene expression in PBMCs was increased in MDD and bipolar depression patients during the depressive, but not remissive, state compared to healthy controls (Shibata et al., 2013). This suggests that increased glycolysis in circulating immune cells reflects and/or contributes to (see 3.2 below) fluctuations in systemic inflammation that have been shown to track with remission of depression (Hannestad et al., 2011; Liu et al., 2020).Table 1 List of glycolytic genes and proteins associated with depressive phenotypes in humans or chronic stress in rodents.

Table 1Publication	Associated phenotype	Immune cell type	Measured by:	Pathway ID (if applicable)	Pathway name (if applicable)	Glycolysis-related genes	
Shibata et al., 2013	Upregulated in MDD vs control during depressive state	Whole blood	qPCR			HIF1A, HIF-1beta (ARNT), VEGF, GLUT1, PGK1, PFKFB3, LDHA	
Remained upregulated in MDD vs control during remissive state	Whole blood	qPCR			HIF1A, LDHA	
Upregulated in BPD vs control during depressive state	Whole blood	qPCR			HIF1A, HIF-1beta (ARNT), VEGF, PFKFB3	
Mehta et al., 2013	Baseline predictors of antidepressant response to infliximab among treatment resistant MD patients	Whole blood	Microarray	MetaCore 930, WikiPathways WP534	Glycolysis and Gluconeogenesis	PGAM4, ENO2, ALDOA	
Bekhbat et al., 2020	High vs low anhedonia among MD patients with high inflammation	Whole blood	Microarray	KEGG hsa04066	HIF-1 signaling	PFKFB3, EGLN1, STAT3, ENO2, MKNK1, PIK3CA, TLR4, PIK3CD, INS, IGF1R, ENO3, IFNGR2, EP300, AKT3, PDK1, MAPK1, ALDOB, HK3, HIF1A, MAP2K2, MKNK2, CAMK2G, CREBBP	
Bekhbat et al., 2021	Psychomotor slowing among MD patients	Whole blood	Microarray	WikiPathways WP4629	Computational Model of Aerobic Glycolysis	PGK1, GAPDH, TPI1, ALDOA	
KEGG hsa00010	Glycolysis/Gluconeogenesis	PGK1, GAPDH, PGAM1, TPI1, ALDOA, PGAM4, DLD, PGM1, ALDH2	
Bekhbat et al., 2022a	Upregulated in MD patients with high vs. low inflammation	CD14+ monocytes	scRNA-Seq	WikiPathways WP4629	Aerobic glycolysis	GAPDH, PKM	
WikiPathways WP3614	Photodynamic therapy-induced HIF-1 survival signaling	SLC2A3, PKM, BNIP3L	
KEGG hsa00010	Glycolysis/Gluconeogenesis	GAPDH, ALDH2, PKM	
KEGG hsa00030	Pentose phosphate pathway	TALDO1, TKT	
Li et al., 2017	Upregulated in susceptible vs. resilient rats subjected to chronic unpredictable mild stress	PBMCs	Metabolomics	IPA	HIF-1 signaling	Pyruvic acid, Lactic acid	
Barrett et al., 2021	Upregulated in chronic variable stress vs. non-stressed mice	Bone marrow monocytes	RNA-Seq			Hif1a, Hmox1, Fau, Pik3c2a, Pik3r5, Prkce, Eif3e, Eif3f	
Lee et al., 2022	Upregulated in subordinate vs. dominant mice in social hierarchies	Spleen cells	RNA-Seq			Pcx, Fkbp4, Cxcr4, Pygb and 18 more genes	
Bekhbat et al., 2023	Upregulated in repeated social defeat vs. non-stressed mice	Spleen macrophages	scRNA-Seq	WikiPathways WP157	Glycolysis and gluconeogenesis	Gapdh, Got1, Eno1, Hk3, Pgam1	
KEGG mmu00010	Glycolysis/Gluconeogenesis	Gapdh, Eno1, Eno1b, Akr1a1, Hk3, Aldh7a1, Pgam1	
KEGG mmu04066	HIF-1 signaling pathway	Gapdh, Rps6, Eno1, Eno1b, Elob, Rbx1, Hk3	
Spleen granulocytes	scRNA-Seq	WikiPathways WP157	Glycolysis and gluconeogenesis	Mpc2, Ldha, Gapdh, Mdh2, Pgk1, Mpc1	
KEGG mmu00010	Glycolysis/Gluconeogenesis	Adpgk, Ldha, Gapdh, Aldh3b1, Pgk1, Aldh2	
Abbreviations: MDD, major depressive disorder; BPD, bipolar depression; MD, major depression (includes bipolar current episode depressed); qPCR, quantitative polymerase chain reaction; scRNA-Seq, single-cell RNA-Seq; KEGG, Kyoto Encyclopedia of Genes and Genomes; IPA, Ingenuity Pathway Analysis; CD14, cluster of differentiation 14; HIF-1, Hypoxia-Inducible Factor-1.

2.2 Monocytes are a main source of glycolysis in depression with high inflammation

Immune cells vary on the spectrum of glycolytic to mitochondrial metabolism, with neutrophils and monocytes displaying the highest level of glycolysis (Kramer et al., 2014). Even within T lymphocytes, which rely mainly on mitochondrial metabolism, immunometabolic programs differ in opposing directions between effector and memory subsets (Bantug et al., 2018). Therefore, variability in the composition of immune cell subsets within whole blood or PBMC admixtures could influence the overall immunometabolic profiles of these bulk samples (Brasanac et al., 2022). For example, lactate production (a byproduct and index of glycolysis) in PBMCs was associated with monocyte percentage within the sample, particularly after stimulation of the cells with various pathogens (Vrieling et al., 2022), suggesting that glycolysis production by PBMCs is either driven in large part by monocytes or reflects inflammation that causes monocytosis.

This is consistent with our earlier finding that immunometabolic whole blood gene pathways associated with anhedonia in MDD with high inflammation were driven by genes estimated to derive from circulating monocytes (Bekhbat et al., 2020). While much of the evidence pointing to monocytes as the source of increased glycolysis in bulk samples is computationally derived, using single-cell RNA-Seq we have reported direct evidence of increased glycolytic gene expression specifically in monocytes (but not other cell types) of MDD patients with higher inflammation (Bekhbat et al., 2022a). In this study, MDD patients with high plasma CRP (>3 mg/L) exhibited a profound enrichment of monocytes expressing CD14 and CD16 compared to patients with low CRP. Genes upregulated in monocytes of high CRP patients enriched inflammatory (phagocytosis, complement, chemotaxis) and immunometabolic pathways (aerobic glycolysis, HIF-1) (Bekhbat et al., 2022a). Moreover, in MDD patients with high inflammation who were administered an anti-inflammatory challenge with infliximab, changes in the number of CD14-expressing monocytes predicted improvements in anhedonia severity. Another study that examined bioenergetics of purified monocytes from MDD patients (without stratification by inflammation) reported trends toward reduced mitochondrial respiration metrics (including significantly lower coupling efficiency) compared to monocytes from non-depressed controls (Gamradt et al., 2021), suggesting that increased glycolysis in MDD monocyte samples may be accompanied by unchanged or lower mitochondrial metabolism. Taken together, these data implicate monocyte glycolytic metabolism as a biomarker of symptom severity in MDD, especially in patients with high inflammation.

It should be noted that while this review focuses on immunometabolism of monocytes as they are a key leukocyte source of systemic inflammation (Vanderbeke et al., 2021; Arango and Descoteaux, 2014) which may in turn impact the brain and behavior in MDD, studies using flow cytometry and scRNA-Seq have identified associations between both myeloid and lymphoid cells and varying aspects of increased inflammation in MDD (Lynall et al., 2019; Bekhbat et al., 2022a). Bioenergetic and gene expression assessments in T cells of MDD patients versus healthy controls have revealed prominent reductions in mitochondrial respiration as well as genes related to mitochondrial fatty acid oxidation (Gamradt et al., 2021). These findings are consistent with results from our MDD scRNA-Seq study, where CD4+ central memory T cells of patients with high inflammation exhibited downregulated genes of the OXPHOS pathway, a primary energy source in this cell type (Bekhbat et al., 2022a). Together, these results affirm a role for CD4+ T cell mitochondrial dysfunction in depression.

2.3 Myeloid cell glycolysis as a biomarker for susceptibility to stress

Chronic stress is a major risk factor for MDD and is linked to systemic inflammation and metabolic alterations like insulin resistance (Black, 2006). At the cellular level, glucocorticoids are recognized for their immediate anti-inflammatory actions (Bekhbat et al., 2017). However, chronic glucocorticoid exposure, typical of sustained stress, has been shown to prime peripheral myeloid cells toward a pro-inflammatory state that drives depressive- and anxiety-like behavior in animal models (Avitsur et al., 2001; Stark et al., 2001).

Recent investigations have uncovered that acute glucocorticoid administration in myeloid cells attenuates glycolysis while enhancing the TCA cycle's activity (Stifel et al., 2022). This mechanism contrasts with the chronic stress response, where prolonged psychosocial stress has been linked to increased glycolysis and changes in several of its upstream pathways, including HIF-1α and its regulators mTOR and PI3K. Specifically, monocytes from mice exposed to continuous variable stress exhibited upregulated gene expression within the PI3K-Akt, mTOR, and HIF-1α pathways, concomitant with a decline in OXPHOS and reduced chromatin accessibility at genomic sites associated with mitochondrial respiration (Barrett et al., 2021). Moreover, behavioral susceptibility to stress has been shown to be associated with increased glycolysis in peripheral immune cells (Lee et al., 2022; Li et al., 2017). Monocytes from chronic stress-exposed mice become primed, and reside in higher numbers in the spleen as an immunologic reservoir (McKim et al., 2018a). Interestingly, some chronic stress studies reported that myeloid cells in the spleen of chronic stress-exposed mice show increased expression of both glycolytic and OXPHOS pathway genes (Bekhbat et al., 2023; Lee et al., 2022), suggesting a hypermetabolic phenotype that may enable cellular proliferation of these cells (see 4.2 below).

Together, these findings indicate that immunometabolic changes within peripheral immune cells involving increased glycolysis may serve as both a biomarker and an underlying mechanism in depression, particularly depression involving high inflammation. Causal relationships between immune cell metabolism and behavioral outcomes, as well as the roles of specific immune cell subsets can be powerfully queried using mouse genetic models. Experiments involving depletion or adoptive transfer of peripheral immune cells have shown that monocytes (Wohleb et al., 2013) and T cells (Fan et al., 2019) play causal roles in the behavioral consequences of chronic stress. Fan et al. (2019) reported that chronic stress reduced OXPHOS and mitochondrial fusion in CD4+ T cells. By transferring CD4+ T cells lacking mitochondrial fusion proteins into lymphocyte-deficient mice, the authors were able to causally link CD4+ T cell mitochondrial metabolism to anxiety-like behavior. Myeloid-specific deletions of glycolytic enzymes such as Pkm2 and Ldha, have been shown to reduce inflammation in diverse settings (Xie et al., 2016; Dhanesha et al., 2022; Flick, 2022; Seth et al., 2017). Therefore, inducible genetic modifications that delete or overexpress glycolytic enzymes, combined with chronic stress models of depression such as the social defeat paradigm, can help elucidate the specific role of monocyte glycolysis in behavioral changes.

3 Glycolytic rewiring enhances inflammatory responses: relevance to MDD

3.1 Role of glycolysis in monocyte subsets and macrophage/microglia polarization

There is evidence that the three main subpopulations of human monocytes are characterized by divergent metabolic gene expression. Classical monocytes (CD14++CD16−) were reported to have the highest expression of glycolytic genes, whereas nonclassical monocytes (CD14dimCD16+) had highest OXPHOS gene expression, with the intermediate subset (CD14+CD16+) falling between these two phenotypes (Schmidl et al., 2014). Within classical or overall monocytes, factors such as aging (Saare et al., 2020; Wang et al., 2023) and elevated circulating inflammation and other soluble factors (Bekhbat et al., 2022a; Giacomello et al., 2023; Wolfe et al., 2019) may be further associated with greater glycolysis. While anti-inflammatory agents have been shown to reduce monocyte numbers, activation, and glycolysis (Cordes et al., 2020; Tucci et al., 2022; Lee et al., 2019), whether metabolic approaches can influence monocyte subsets and phenotypes is not as clear.

Macrophages, which differentiate from circulating monocytes upon their tissue entry, also exhibit distinct immunometabolic programs that not only vary between macrophage subtypes but in part determine their polarization into these subtypes (Wculek et al., 2022). Classically activated macrophages (induced by stimulation with interferon-gamma [INF-γ] and/or lipopolysaccharide [LPS], also referred to as M1-like) display increased glycolysis. Simultaneously, these macrophages display a “broken TCA cycle” where the TCA intermediates succinate and citrate build up and promote HIF-1α stabilization and the generation of cytokines, nitric oxide, and prostaglandins, thus perpetuating glycolysis and inflammatory responses further (Infantino et al., 2011; Tannahill et al., 2013). In contrast, alternatively activated macrophages (induced by IL-4, also known as M2-like) have an intact TCA cycle along with increased fatty acid oxidation (Mills and O'Neill, 2016). Similar immunometabolic programs govern the phenotype of other myeloid cells of interest in MDD, including adipose tissue macrophages (Kohlgruber et al., 2016) and microglia (Song et al., 2022). However, the impact of metabolism on the differentiation and function of perivascular macrophages has not been studied and would be of interest in depression (see 3.4 below).

3.2 Activation of the inflammasome and cytokine release

Glycolysis supports the activation of inflammasomes and the production of cytokines, key outcomes of myeloid cell stimulation through various mechanisms (Hughes and O'Neill, 2018). For example, in LPS-treated macrophages the rate-limiting glycolytic enzyme PKM2 forms a complex with Hif-1α, binding directly to the IL-1β promoter and enhancing its expression (Palsson-McDermott et al., 2015). Moreover, in a mouse model of sepsis, PKM2 has been shown to activate the NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) and AIM2 (absent in melanoma 2) inflammasomes, leading to caspase 1-dependent processing and release of IL-1β, IL-18, and high mobility group box 1 (HMGB1) (Xie et al., 2016). Pharmacologic or genetic inhibition of glycolytic enzymes, as well as the commonly used glycolysis inhibitor 2-deoxy-D-glucose (2-DG), a glucose analog that cannot be further metabolized, abrogate LPS-induced cytokine production (Xie et al., 2016; Zhang et al., 2019; Dietl et al., 2010). In addition, signals derived from glycolytic rewiring (such as the broken TCA intermediate succinate) support the production of cytokines, most notably IL-1β (Tannahill et al., 2013). Interestingly, in autoimmune conditions such as type 1 diabetes mellitus, monocyte glycolysis and cytokine production may become uncoupled (Vrieling et al., 2022; Thiem et al., 2020). Other examples of glycolysis enhancement of inflammation gone awry in disease include the role of glycolysis in enabling SARS-CoV-2 infection of monocytes and the subsequent cytokine storm (Codo et al., 2020) as well as promoting and sustaining HIV-1 viral persistence and reactivation of myeloid viral reservoirs (Real et al., 2022; Shytaj et al., 2021). Pilot data from MDD patients suggests that monocyte glycolytic state associates with circulating inflammation levels (measured by CRP) as well as anhedonia severity (Bekhbat et al., 2022b). Further investigation of the role of glycolysis in promoting systemic inflammation in MDD is currently underway.

3.3 Reactive oxygen species generation and cellular proliferation

Upon myeloid cell activation, along with a shift to glycolysis, concurrent changes occur to related metabolic pathways such as an upregulation of the pentose phosphate pathway, which supplies the reducing agent NADPH necessary for reactive oxygen species generation (O'Neill et al., 2016). In addition, other products resulting from glycolysis, glutaminolysis, and pentose phosphate pathway including amino acids, fatty acids, and nucleotides also provide biosynthetic material needed for rapid cellular proliferation (Ganeshan and Chawla, 2014).

3.4 Migration

Emerging studies have suggested a critical role for cellular metabolism in regulating immune cell motility and migration. By definition, monocytes are highly motile immune cells that traffic to regions of inflammation and damage. Migrating cells have glycolytic metabolism (Kathagen-Buhmann et al., 2016), which in turn increases monocytic markers that are associated with trafficking, including chemokine receptors and adhesion molecules (Schioppa et al., 2003). Glycolysis is also required for the cytoskeleton remodeling that enables migration (Guak and Krawczyk, 2020; Marelli-Berg and Jangani, 2018). Inhibition of glycolysis via blocking glycolytic enzymes or deficiency of HIF-1α reduces monocyte transmigration (Hara et al., 2017; Semba et al., 2016; Kaushik et al., 2019; Cramer et al., 2003). These studies suggest that glycolysis is necessary for migration.

The relevance of peripheral monocyte trafficking to the brain in depression and other behavioral changes associated with inflammation is supported by a wealth of pre-clinical and translational, as well as limited clinical data. Mechanistic studies in rodent models of social defeat stress demonstrate that Ly6Chi monocytes expressing CCR2 (C-C chemokine receptor type 2) traffic to the parenchyma and perivascular spaces in the brain and lead to the production of inflammatory cytokines that are essential for the development of stress-induced behavioral changes (Wohleb et al., 2013, 2014; Sawicki et al., 2015; McKim et al., 2016, 2018b; Menard et al., 2017; Dudek et al., 2020; Dion-Albert et al., 2022). Increased number and in vitro blood-brain barrier (BBB) transmigration of monocytes, particularly those that express trafficking markers like CCR2, are associated with neurocognitive impairments in people with HIV (Veenhuis et al., 2021; Williams et al., 2014). Finally, increased perivascular monocytes/macrophages have been identified in postmortem brains of depressed patients who committed suicide (Torres-Platas et al., 2014). In light of these findings, whether monocyte glycolytic reprograming promotes immune-to-brain communication in association with behavioral symptoms is a topic that is being actively investigated (e.g., Bekhbat et al. (2023) and the ongoing NIMH-funded project 1K01MH136861-01 examining the role of monocyte metabolism and BBB transmigration in symptoms of anhedonia in people with HIV).

In addition to the above-mentioned investigations of the mechanistic role of myeloid glycolysis in MDD pathophysiology, several other questions warrant further examination as follows.

4 Outstanding questions and future directions

4.1 Relevance of glycolytic shift to energy availability and expenditure in the context of MDD

Inflammation is reliably associated with depressive symptoms characterized by reduced energy expenditure such as anhedonia, which involves decreases in effort-based motivation for reward (Treadway and Zald, 2011; Treadway et al., 2012), and psychomotor slowing (Carvalho et al., 2014; Goldsmith et al., 2016). Both symptoms (Bekhbat et al., 2020, 2021, 2022a, 2022b) and changes to relevant neural circuitry (Goldsmith et al., 2020) have been associated with markers of glycolysis, which generates a fraction of energy that can be produced from OXPHOS. Additionally, inflammation is also linked to fatigue, which involves a perceived lack of energy (Lacourt et al., 2018). Whether lower ATP production through glycolysis is a cause of low energy availability is currently unclear.

A more likely scenario is that increased glycolysis is an indicator and driver of inflammatory states associated with increased energy consumption and anabolic metabolism (Wang et al., 2019). For instance, during infection the innate immune response, which relies more heavily on increased glycolysis, drives most of the systemic metabolic demand, with the maximal adaptive immune response occurring once metabolic homeostasis has been re-established (Johnson et al., 2020). Additionally, patients with mitochondrial disorders who have OXPHOS defects and compensatory increases in glycolysis also display increased resting energy expenditure and fatigue (Sturm et al., 2023). At a systemic level, increased energy demand in the immune system, which is a compartment that is in large parts physically separated from the brain, is thought to be communicated to the brain through hypothalamic axes coordinating metabolic resources toward growth, reproduction, and maintenance programs (Wang et al., 2019). The resulting behavioral adaptations (i.e., sickness behaviors such as decreased nutrient uptake and hypersomnia) aim to increase energy-saving, catabolic metabolism (Wang et al., 2019) that then may serve to move cellular immunometabolism from immune resistance/defense (glycolysis) to tolerance/dormancy (e.g., OXPHOS) states. Whether myeloid glycolysis inhibition presents a viable target to reduce resting energy expenditure in MDD and mitigate symptoms of anhedonia and psychomotor slowing is an important question that should be addressed. Moreover, the extent to which increased energy consumption through peripheral immunometabolic shifts compromises the brain's energy demands needs further investigation. Similar to immune defense programs, energy-requiring CNS processes like synaptic growth, plasticity, and learning are supported in part by aerobic glycolysis (Diaz-Garcia et al., 2017; Shannon et al., 2016; Li et al., 2023). Emerging research from neurodegenerative diseases evaluating aerobic glycolysis in neurons as well as central and peripheral immune cells may shed more light on this topic (de Geus et al., 2023; Goyal et al., 2023; Schmidt et al., 2023).

4.2 Concurrent change to OXPHOS during glycolytic rewiring

Much of the existing literature on immunometabolic regulation of immune cell function has utilized LPS, which signals through a toll-like receptor 4 (TLR4) cascade. It is well known that LPS-activated myeloid cells undergo increased glycolysis along with reduced OXPHOS, similar to the classic Warburg effect. However, emerging reports suggest that non-LPS pathogens (particularly those not signaling through TLR4) increase both glycolysis and OXPHOS (Lachmandas et al., 2016; Keating et al., 2016; Kumar et al., 2019; Janzic et al., 2023; Boutens et al., 2018; Hong et al., 2022). This concurrent upregulation of OXPHOS is thought to facilitate the survival, proliferation, and effector functions of immune cells such as cytokine production and phagocytosis. Interestingly, metabolic DAMPs appear to simultaneously augment glycolysis and OXPHOS (Hu et al., 2020; Ratter et al., 2021; Di Gioia et al., 2020), resembling the hypermetabolic and hyper-inflammatory phenotype induced by non-LPS pathogens. In contrast, a metabolic deficit induced by fasting can shift bone marrow myeloid cells from a hypermetabolic state to a more quiescent metabolic profile characterized by decreased glycolysis and OXPHOS, leading to a reduction in their release from the bone marrow into the bloodstream (Jordan et al., 2019).

In the case of proliferating cells, which are known to exhibit a hypermetabolic phenotype, concurrent increase in aerobic glycolysis has been shown to result from glycolysis outpacing mitochondrial NADH shuttles (Wang et al., 2022) whereas increase in mitochondrial OXPHOS was shown to be mediated by mitochondrial fusion (Yao et al., 2019). It has been suggested that psychosocial stress-induced proliferation and differentiation of myeloid reservoirs within the spleen may rely on increased glycolysis, along with increased OXPHOS (Bekhbat et al., 2023; Lee et al., 2022). Future studies on the role of OXPHOS in myeloid cell activation and function will contribute to identification of more specific immunomodulatory approaches in MDD.

5 Repurposing immunometabolic modulators as therapies for MDD

Given that elevated inflammation promotes resistance to standard antidepressant therapies, interest in immunomodulatory treatment of psychiatric illnesses with increased inflammation is high. Unlike non-specific anti-inflammatory agents (Eyre et al., 2015; Rosenblat and McIntyre, 2018; Husain et al., 2020), anti-cytokine therapies have shown efficacy for specific depressive symptoms (notably anhedonia) when targeted to patients with increased inflammation (Raison et al., 2013; Salvadore et al., 2018; Lee et al., 2020). However, anti-cytokine therapies have substantial safety risks and limited use as antidepressants (Dreyer et al., 2016; Miller et al., 2017). Monocyte glycolysis and related immunometabolic reprograming needed to sustain cellular activation may serve as alternative targets for reducing inflammation and its effects on the brain and behavior.

Glycolysis and related pathways such as mTOR and nuclear factor-erythroid factor 2-related factor 2 (Nrf2) can be uniquely targeted by FDA-approved therapies for autoimmune, inflammatory, and metabolic disorders as well as experimental drugs in development (see Table 2) (Palsson-McDermott and O'Neill, 2020). Dimethyl Fumarate (DMF), a treatment for relapsing remitting multiple sclerosis, inhibits pro-glycolytic shifts and inflammatory cytokine production in humans and mice, both in vivo and in vitro (Kornberg et al., 2018). Crucially, DMF only targets immune cells relying on aerobic glycolysis (e.g., activated macrophages, Th1 and Th17 cells), while sparing resting macrophages or regulatory T cells. Rapamycin, an inhibitor of mTORC1 signaling and glycolysis (Lee et al., 2019), has been shown to enhance the antidepressant effect of ketamine, the response to which has been predicted by increased inflammatory markers (Abdallah et al., 2020; Yang et al., 2015). Itaconate is a promising approach to target metabolic pathways specifically in activated myeloid cells (O'Neill and Artyomov, 2019; Peace and O'Neill, 2022). An endogenous anti-inflammatory molecule derived from the TCA cycle, itaconate has been shown to reverse glycolysis-related oxidative stress, and prevent LPS-induced depressive-like behavior in mice (Dantzer, 2021). Finally, 2-DG, a potent glycolysis inhibitor, is well tolerated at low doses in phase I trials, with some showing favorable early clinical outcomes in cancer (Raez et al., 2013; Stein et al., 2010). To take advantage of these therapeutic opportunities in psychiatry, a more nuanced understanding of the cellular metabolic processes that enable immune cell/monocyte activation is required.Table 2 Immunometabolic modulators with potential applicability to MDD.

Table 2Drug	Molecular target	Clinical indication	Effect on cellular metabolism & function, or behavior; Advantages	Brain penetrance	
Dimethyl Fumarate	Nrf2	Multiple sclerosis, psoriasis	• Specifically targets glycolytically active immune cells

• Limits leukocyte entry to the brain

	Derivative (MMF)-yes	
Rapamycin	Inhibition of mTORC1	Prevention of organ rejection, cancer	• Reduces monocyte glycolysis and adhesion

• Prolongs ketamine's antidepressant effects

	Low	
2-DG	Hexokinase	N/A. Pre-clinical applications	• Potent inhibitor of glycolysis

• Reduces monocyte transmigration, adhesion

• Some clinical evidence of safety & efficacy

	Yes	
Itaconate	Succinate dehydrogenase, Nrf2	N/A. Pre-clinical applications	• Specifically targets activated macrophages/monocytes

• Endogenous, low toxicity

	Derivatives-likely	
Abbreviations: Nrf2, Nuclear factor erythroid 2-related factor 2; mTORC1, mechanistic target of rapamycin complex 1; 2-DG, 2-deoxy-D-glucose; MMF, monomethyl fumarate (active metabolite of dimethyl fumarate).

It's currently unclear whether immunometabolic therapies need to target the brain, the immune system, or both to improve behavior. Most drugs in Table 2 or their derivates cross the BBB, albeit to varying degrees. For instance, 2-DG, a glucose analog, readily crosses the BBB (Hasselbalch et al., 1996). DMF quickly metabolizes into its active ingredient monomethyl fumarate (MMF), which crosses the BBB to provide neuroprotection (Edwards et al., 2021). Although itaconate itself likely doesn't penetrate the brain, its derivatives, such as dimethyl itaconate and 4-octyl itaconate, reduce neuroinflammation and improve outcomes in various CNS disease models (Liu et al., 2023). Rapamycin, thought to have low brain penetrance (Brandt et al., 2018), was nevertheless detectable in the brain tumor tissue of patients on oral rapamycin (Cloughesy et al., 2008). As CNS diseases often involve extensive BBB breaches, it's unclear if these molecules can cross the BBB in non-pathological conditions.

On the other hand, all molecules in Table 2 have been shown to alter peripheral inflammation by modulating glycolytic or related metabolic processes in immune cells, as described above. Importantly, inhibition of peripheral blood cytokines using anti-cytokine treatments that do not cross the BBB nonetheless blocks depressive-like behavior in rodents (Bayramgurler et al., 2013; O'Connor et al., 2009), while also reducing depressive symptoms in patients with autoimmune and inflammatory disorders as well as otherwise medically-healthy MD patients with increased inflammation (Raison et al., 2013; Salvadore et al., 2018; Kappelmann et al., 2018; McIntyre et al., 2019). Therefore, it is possible that immunometabolic therapies need only target the immune system to revert inflammation-related changes to the brain and behavior.

6 Conclusions

Given that peripheral monocytes show evidence of glycolytic activation in depression and relevant pre-clinical models, determining the immunometabolic phenotypes of monocytes known to be elevated in MDD with high inflammation is a critical next step to better understanding and treating the effects of inflammation on the brain. These investigations will be greatly aided by the novel application of existing immunomodulatory approaches to depression, which in turn can serve as a foundation for developing new therapies that target the immune system to treat depressive symptoms such as anhedonia and psychomotor slowing.

CRediT authorship contribution statement

Mandakh Bekhbat: Writing – review & editing, Writing – original draft, Visualization, Conceptualization.

Declaration of competing interest

None.

Dr. Mandakh Bekhbat is an Assistant Professor in the Department of Psychiatry and Behavioral Sciences at Emory School of Medicine. Her research combines translational and clinical approaches to understand the neuroimmune and endocrine basis of psychiatric illnesses and identify mechanisms for developing novel treatments. Dr. Bekhbat's work in depressed patients examines metabolic shifts within circulating immune cells that influence their inflammatory phenotypes. These cellular immunometabolic shifts are hypothesized to contribute to systemic inflammation and its effects on the brain and behavior, particularly symptoms of anhedonia. Most recently, she has extended this work to examine immune cell metabolic pathways that contribute to the impact of inflammation on the brain and depressive symptoms in patients with HIV, work that was supported by a KL2 award from the Georgia Clinical and Translational Science Alliance and expanded under a K01 award from the National Institute of Mental Health. Mandy obtained her undergraduate education at Vassar College in 2013, and began her career in psychoneuroimmunology research through her PhD training in the laboratory of Dr. Gretchen Neigh at Emory University and Virginia Commonwealth University as well as postdoctoral training under the mentorship of Dr. Jennifer Felger at Emory University. She was recently appointed to faculty in the Department of Psychiatry and Behavioral Sciences at Emory and the Emory Behavioral Immunology Program led by Dr. Andrew Miller. Mandy is looking forward to establishing a research program spanning basic, translational, and clinical settings that is focused on designing novel immunometabolic treatment strategies for depression and other psychiatric disorders associated with increased inflammation.

Data availability

No data was used for the research described in the article.

Acknowledgements

This work was supported by 10.13039/100000025 NIMH grant K01MH136861 and NIH/10.13039/100006108 NCATS grants KL2TR002381 and UL1TR002378 .
==== Refs
References

Abdallah C.G. Averill L.A. Gueorguieva R. Goktas S. Purohit P. Ranganathan M. Sherif M. Ahn K.H. D'Souza D.C. Formica R. Southwick S.M. Duman R.S. Sanacora G. Krystal J.H. Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin Neuropsychopharmacology 45 6 2020 990 997 32092760
Arango Duque G. Descoteaux A. Macrophage cytokines: involvement in immunity and infectious diseases Front. Immunol. 5 2014 491 25339958
Avitsur R. Stark J.L. Sheridan J.F. Social stress induces glucocorticoid resistance in subordinate animals Horm. Behav. 39 4 2001 247 257 11374910
Bantug G.R. Galluzzi L. Kroemer G. Hess C. The spectrum of T cell metabolism in health and disease Nat. Rev. Immunol. 18 1 2018 19 34 28944771
Barrett T.J. Corr E.M. van Solingen C. Schlamp F. Brown E.J. Koelwyn G.J. Lee A.H. Shanley L.C. Spruill T.M. Bozal F. de Jong A. Newman A.A.C. Drenkova K. Silvestro M. Ramkhelawon B. Reynolds H.R. Hochman J.S. Nahrendorf M. Swirski F.K. Fisher E.A. Berger J.S. Moore K.J. Chronic stress primes innate immune responses in mice and humans Cell Rep. 36 10 2021 109595
Bayramgurler D. Karson A. Ozer C. Utkan T. Effects of long-term etanercept treatment on anxiety- and depression-like neurobehaviors in rats Physiol. Behav. 119 2013 145 148 23769689
Bekhbat M. Rowson S.A. Neigh G.N. Checks and balances: the glucocorticoid receptor and NFkB in good times and bad Front. Neuroendocrinol. 46 2017 15 31 28502781
Bekhbat M. Treadway M.T. Goldsmith D.R. Woolwine B.J. Haroon E. Miller A.H. Felger J.C. Gene signatures in peripheral blood immune cells related to insulin resistance and low tyrosine metabolism define a sub-type of depression with high CRP and anhedonia Brain Behav. Immun. 88 2020 161 165 32198016
Bekhbat M. Goldsmith D.R. Woolwine B.J. Haroon E. Miller A.H. Felger J.C. Transcriptomic signatures of psychomotor slowing in peripheral blood of depressed patients: evidence for immunometabolic reprogramming Mol. Psychiatr. 26 12 2021 7384 7392
Bekhbat M. Ulukaya G.B. Bhasin M.K. Felger J.C. Miller A.H. Cellular and immunometabolic mechanisms of inflammation in depression: preliminary findings from single cell RNA sequencing and a tribute to Bruce McEwen Neurobiol Stress 19 2022 100462
Bekhbat M. Ulukaya G.B. Nesbeth P.-D.C. Bhasin M.K. Alvarez J.A. Miller A.H. Felger J.C. P236. Immunometabolic signatures in monocytes are associated with anhedonia in depressed patients with high inflammation Biol. Psychiatr. 91 9 2022 S182 S183
Bekhbat M. Drake J. Reed E.C. Lauten T.H. Natour T. Vladimirov V.I. Case A.J. Repeated social defeat stress leads to immunometabolic shifts in innate immune cells of the spleen Brain Behav Immun Health 34 2023 100690
Black P.H. The inflammatory consequences of psychologic stress: relationship to insulin resistance, obesity, atherosclerosis and diabetes mellitus, type II Med. Hypotheses 67 4 2006 879 891 16781084
Boutens L. Hooiveld G.J. Dhingra S. Cramer R.A. Netea M.G. Stienstra R. Unique metabolic activation of adipose tissue macrophages in obesity promotes inflammatory responses Diabetologia 61 4 2018 942 953 29333574
Brandt C. Hillmann P. Noack A. Romermann K. Ohler L.A. Rageot D. Beaufils F. Melone A. Sele A.M. Wymann M.P. Fabbro D. Loscher W. The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy Neuropharmacology 140 2018 107 120 30081001
Brasanac J. Gamradt S. Otte C. Milaneschi Y. Monzel A.S. Picard M. Gold S.M. Cellular specificity of mitochondrial and immunometabolic features in major depression Mol. Psychiatr. 27 5 2022 2370 2371
Carvalho A.F. Miskowiak K.K. Hyphantis T.N. Kohler C.A. Alves G.S. Bortolato B. PM G.S. Machado-Vieira R. Berk M. McIntyre R.S. Cognitive dysfunction in depression - pathophysiology and novel targets CNS Neurol. Disord.: Drug Targets 13 10 2014 1819 1835 25470397
Chae W.R. Baumert J. Nubel J. Brasanac J. Gold S.M. Hapke U. Otte C. Associations between individual depressive symptoms and immunometabolic characteristics in major depression Eur. Neuropsychopharmacol 71 2023 25 40 36966710
Chamberlain S.R. Cavanagh J. de Boer P. Mondelli V. Jones D.N.C. Drevets W.C. Cowen P.J. Harrison N.A. Pointon L. Pariante C.M. Bullmore E.T. Treatment-resistant depression and peripheral C-reactive protein Br. J. Psychiatry 2018 1 9
Cloughesy T.F. Yoshimoto K. Nghiemphu P. Brown K. Dang J. Zhu S. Hsueh T. Chen Y. Wang W. Youngkin D. Liau L. Martin N. Becker D. Bergsneider M. Lai A. Green R. Oglesby T. Koleto M. Trent J. Horvath S. Mischel P.S. Mellinghoff I.K. Sawyers C.L. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma PLoS Med. 5 1 2008 e8
Codo A.C. Davanzo G.G. Monteiro L.B. de Souza G.F. Muraro S.P. Virgilio-da-Silva J.V. Prodonoff J.S. Carregari V.C. de Biagi Junior C.A.O. Crunfli F. Jimenez Restrepo J.L. Vendramini P.H. Reis-de-Oliveira G. Bispo Dos Santos K. Toledo-Teixeira D.A. Parise P.L. Martini M.C. Marques R.E. Carmo H.R. Borin A. Coimbra L.D. Boldrini V.O. Brunetti N.S. Vieira A.S. Mansour E. Ulaf R.G. Bernardes A.F. Nunes T.A. Ribeiro L.C. Palma A.C. Agrela M.V. Moretti M.L. Sposito A.C. Pereira F.B. Velloso L.A. Vinolo M.A.R. Damasio A. Proenca-Modena J.L. Carvalho R.F. Mori M.A. Martins-de-Souza D. Nakaya H.I. Farias A.S. Moraes-Vieira P.M. Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1alpha/Glycolysis-Dependent Axis Cell Metabol. 32 3 2020 437 446 e5
Cordes F. Lenker E. Spille L.J. Weinhage T. Bettenworth D. Kessel C. Schmidt H.H. Foell D. Varga G. Tofacitinib reprograms human monocytes of IBD patients and healthy controls toward a more regulatory phenotype Inflamm. Bowel Dis. 26 3 2020 391 406 31560043
Cramer T. Yamanishi Y. Clausen B.E. Forster I. Pawlinski R. Mackman N. Haase V.H. Jaenisch R. Corr M. Nizet V. Firestein G.S. Gerber H.P. Ferrara N. Johnson R.S. HIF-1alpha is essential for myeloid cell-mediated inflammation Cell 112 5 2003 645 657 12628185
DIgnazio L. Bandarra D. Rocha S. NF-kappaB and HIF crosstalk in immune responses FEBS J. 283 3 2016 413 424 26513405
Dantzer R. The Metabolic Basis of Inflammation-Induced Depression 2021 PsychoNeuroImmunology Research Society Annual Meeting; Virtual
Dantzer R. Walker A.K. Is there a role for glutamate-mediated excitotoxicity in inflammation-induced depression? J. Neural. Transm. 121 8 2014 925 932 24633997
Dantzer R. Casaril A. Vichaya E. Inflammation and Depression: Is Immunometabolism the Missing Link? Immuno-Psychiatry 2021 259 287
de Geus M.B. Leslie S.N. Lam T. Wang W. Roux-Dalvai F. Droit A. Kivisakk P. Nairn A.C. Arnold S.E. Carlyle B.C. Mass spectrometry in cerebrospinal fluid uncovers association of glycolysis biomarkers with Alzheimer's disease in a large clinical sample Sci. Rep. 13 1 2023 22406
Dhanesha N. Patel R.B. Doddapattar P. Ghatge M. Flora G.D. Jain M. Thedens D. Olalde H. Kumskova M. Leira E.C. Chauhan A.K. PKM2 promotes neutrophil activation and cerebral thromboinflammation: therapeutic implications for ischemic stroke Blood 139 8 2022 1234 1245 34529778
Di Gioia M. Spreafico R. Springstead J.R. Mendelson M.M. Joehanes R. Levy D. Zanoni I. Endogenous oxidized phospholipids reprogram cellular metabolism and boost hyperinflammation Nat. Immunol. 21 1 2020 42 53 31768073
Diaz-Garcia C.M. Mongeon R. Lahmann C. Koveal D. Zucker H. Yellen G. Neuronal stimulation triggers neuronal glycolysis and not lactate uptake Cell Metabol. 26 2 2017 361 374 e4
Dietl K. Renner K. Dettmer K. Timischl B. Eberhart K. Dorn C. Hellerbrand C. Kastenberger M. Kunz-Schughart L.A. Oefner P.J. Andreesen R. Gottfried E. Kreutz M.P. Lactic acid and acidification inhibit TNF secretion and glycolysis of human monocytes J. Immunol. 184 3 2010 1200 1209 20026743
Dion-Albert L. Cadoret A. Doney E. Kaufmann F.N. Dudek K.A. Daigle B. Parise L.F. Cathomas F. Samba N. Hudson N. Lebel M. Signature C. Campbell M. Turecki G. Mechawar N. Menard C. Vascular and blood-brain barrier-related changes underlie stress responses and resilience in female mice and depression in human tissue Nat. Commun. 13 1 2022 164 35013188
Dreyer L. Magyari M. Laursen B. Cordtz R. Sellebjerg F. Locht H. Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry Ann. Rheum. Dis. 75 4 2016 785 786 26698850
Dudek K.A. Dion-Albert L. Lebel M. LeClair K. Labrecque S. Tuck E. Ferrer Perez C. Golden S.A. Tamminga C. Turecki G. Mechawar N. Russo S.J. Menard C. Molecular adaptations of the blood-brain barrier promote stress resilience vs. depression Proc. Natl. Acad. Sci. U.S.A. 117 6 2020 3326 3336 31974313
Edwards K.R. Kamath A. Button J. Kamath V. Mendoza J.P. Zhu B. Plavina T. Woodward C. Penner N. A pharmacokinetic and biomarker study of delayed-release dimethyl fumarate in subjects with secondary progressive multiple sclerosis: evaluation of cerebrospinal fluid penetration and the effects on exploratory biomarkers Mult Scler Relat Disord 51 2021 102861
Eyre H.A. Air T. Proctor S. Rositano S. Baune B.T. A critical review of the efficacy of non-steroidal anti-inflammatory drugs in depression Prog. Neuro-Psychopharmacol. Biol. Psychiatry 57 2015 11 16
Fan K.Q. Li Y.Y. Wang H.L. Mao X.T. Guo J.X. Wang F. Huang L.J. Li Y.N. Ma X.Y. Gao Z.J. Chen W. Qian D.D. Xue W.J. Cao Q. Zhang L. Shen L. Zhang L. Tong C. Zhong J.Y. Lu W. Lu L. Ren K.M. Zhong G. Wang Y. Tang M. Feng X.H. Chai R.J. Jin J. Stress-induced metabolic disorder in peripheral CD4(+) T cells leads to anxiety-like behavior Cell 179 4 2019 864 879 e19 31675497
Felger J.C. Imaging the role of inflammation in mood and anxiety-related disorders Curr. Neuropharmacol. 16 5 2018 533 558 29173175
Felger J.C. Treadway M.T. Inflammation effects on motivation and motor activity: role of dopamine Neuropsychopharmacology 42 1 2017 216 241 27480574
Felger J.C. Mun J. Kimmel H.L. Nye J.A. Drake D.F. Hernandez C.R. Freeman A.A. Rye D.B. Goodman M.M. Howell L.L. Miller A.H. Chronic interferon-alpha decreases dopamine 2 receptor binding and striatal dopamine release in association with anhedonia-like behavior in nonhuman primates Neuropsychopharmacology 38 11 2013 2179 2187 23657438
Felger J.C. Li L. Marvar P.J. Woolwine B.J. Harrison D.G. Raison C.L. Miller A.H. Tyrosine metabolism during interferon-alpha administration: association with fatigue and CSF dopamine concentrations Brain Behav. Immun. 31 2013 153 160 23072726
Felger J.C. Hernandez C.R. Miller A.H. Levodopa reverses cytokine-induced reductions in striatal dopamine release Int. J. Neuropsychopharmacol./official scientific journal of the Collegium Internationale Neuropsychopharmacologicum 18 4 2015 1 5
Flick M.J. Targeting neutrophil PKM2 for stroke treatment Blood 139 8 2022 1131 1132 35201329
Gamradt S. Hasselmann H. Taenzer A. Brasanac J. Stiglbauer V. Sattler A. Sajitz-Hermstein M. Kierszniowska S. Ramien C. Nowacki J. Mascarell-Maricic L. Wingenfeld K. Piber D. Strohle A. Kotsch K. Paul F. Otte C. Gold S.M. Reduced mitochondrial respiration in T cells of patients with major depressive disorder iScience 24 11 2021 103312
Ganeshan K. Chawla A. Metabolic regulation of immune responses Annu. Rev. Immunol. 32 2014 609 634 24655299
Giacomello G. Otto C. Priller J. Ruprecht K. Bottcher C. Parr M.K. 1,2-(13)C(2)-Glucose tracing approach to assess metabolic alterations of human monocytes under neuroinflammatory conditions Curr. Issues Mol. Biol. 45 1 2023 765 781 36661537
Goldsmith D.R. Haroon E. Woolwine B.J. Jung M.Y. Wommack E.C. Harvey P.D. Treadway M.T. Felger J.C. Miller A.H. Inflammatory markers are associated with decreased psychomotor speed in patients with major depressive disorder Brain Behav. Immun. 56 2016 281 288 27040122
Goldsmith D.R. Bekhbat M. Le N.A. Chen X. Woolwine B.J. Li Z. Haroon E. Felger J.C. Protein and gene markers of metabolic dysfunction and inflammation together associate with functional connectivity in reward and motor circuits in depression Brain Behav. Immun. 88 2020 193 202 32387344
Goyal M.S. Blazey T. Metcalf N.V. McAvoy M.P. Strain J.F. Rahmani M. Durbin T.J. Xiong C. Benzinger T.L. Morris J.C. Raichle M.E. Vlassenko A.G. Brain aerobic glycolysis and resilience in Alzheimer disease Proc. Natl. Acad. Sci. U.S.A. 120 7 2023 e2212256120
Guak H. Krawczyk C.M. Implications of cellular metabolism for immune cell migration Immunology 161 3 2020 200 208 32920838
Hannestad J. DellaGioia N. Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis Neuropsychopharmacology 36 2011
Hara T. Nakaoka H.J. Hayashi T. Mimura K. Hoshino D. Inoue M. Nagamura F. Murakami Y. Seiki M. Sakamoto T. Control of metastatic niche formation by targeting APBA3/Mint3 in inflammatory monocytes Proc. Natl. Acad. Sci. U.S.A. 114 22 2017 E4416 E4424 28507122
Haroon E. Woolwine B.J. Chen X. Pace T.W. Parekh S. Spivey J.R. Hu X.P. Miller A.H. IFN-alpha-induced cortical and subcortical glutamate changes assessed by magnetic resonance spectroscopy Neuropsychopharmacology 39 7 2014 1777 1785 24481242
Haroon E. Fleischer C.C. Felger J.C. Chen X. Woolwine B.J. Patel T. Hu X.P. Miller A.H. Conceptual convergence: increased inflammation is associated with increased basal ganglia glutamate in patients with major depression Mol. Psychiatr. 21 10 2016 1351 1357
Haroon E. Daguanno A.W. Woolwine B.J. Goldsmith D.R. Baer W.M. Wommack E.C. Felger J.C. Miller A.H. Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder Psychoneuroendocrinology 95 2018 43 49 29800779
Haroon E. Chen X. Li Z. Patel T. Woolwine B.J. Hu X.P. Felger J.C. Miller A.H. Increased inflammation and brain glutamate define a subtype of depression with decreased regional homogeneity, impaired network integrity, and anhedonia Transl. Psychiatry 8 1 2018 189 30202011
Hasselbalch S.G. Knudsen G.M. Holm S. Hageman L.P. Capaldo B. Paulson O.B. Transport of D-glucose and 2-fluorodeoxyglucose across the blood-brain barrier in humans J. Cerebr. Blood Flow Metabol. 16 4 1996 659 666
Hong H.S. Mbah N.E. Shan M. Loesel K. Lin L. Sajjakulnukit P. Correa L.O. Andren A. Lin J. Hayashi A. Magnuson B. Chen J. Li Z. Xie Y. Zhang L. Goldstein D.R. Carty S.A. Lei Y.L. Opipari A.W. Arguello R.J. Kryczek I. Kamada N. Zou W. Franchi L. Lyssiotis C.A. OXPHOS promotes apoptotic resistance and cellular persistence in T(H)17 cells in the periphery and tumor microenvironment Sci Immunol. 7 77 2022 eabm8182
Hu Y. Mai W. Chen L. Cao K. Zhang B. Zhang Z. Liu Y. Lou H. Duan S. Gao Z. mTOR-mediated metabolic reprogramming shapes distinct microglia functions in response to lipopolysaccharide and ATP Glia 68 5 2020 1031 1045 31793691
Hughes M.M. ONeill L.A.J. Metabolic regulation of NLRP3 Immunol. Rev. 281 1 2018 88 98 29247992
Husain M.I. Chaudhry I.B. Khoso A.B. Husain M.O. Hodsoll J. Ansari M.A. Naqvi H.A. Minhas F.A. Carvalho A.F. Meyer J.H. Deakin B. Mulsant B.H. Husain N. Young A.H. Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial Lancet Psychiatr. 7 6 2020 515 527
Infantino V. Convertini P. Cucci L. Panaro M.A. Di Noia M.A. Calvello R. Palmieri F. Iacobazzi V. The mitochondrial citrate carrier: a new player in inflammation Biochem. J. 438 3 2011 433 436 21787310
Janzic L. Repas J. Pavlin M. Zemljic-Jokhadar S. Ihan A. Kopitar A.N. Macrophage polarization during Streptococcus agalactiae infection is isolate specific Front. Microbiol. 14 2023 1186087
Johnson R.M. Olatunde A.C. Woodie L.N. Greene M.W. Schwartz E.H. The systemic and cellular metabolic phenotype of infection and immune response to Listeria monocytogenes Front. Immunol. 11 2020 614697
Jordan S. Tung N. Casanova-Acebes M. Chang C. Cantoni C. Zhang D. Wirtz T.H. Naik S. Rose S.A. Brocker C.N. Gainullina A. Hornburg D. Horng S. Maier B.B. Cravedi P. LeRoith D. Gonzalez F.J. Meissner F. Ochando J. Rahman A. Chipuk J.E. Artyomov M.N. Frenette P.S. Piccio L. Berres M.L. Gallagher E.J. Merad M. Dietary intake regulates the circulating inflammatory monocyte pool Cell 178 5 2019 1102 1114 e17 31442403
Kappelmann N. Lewis G. Dantzer R. Jones P.B. Khandaker G.M. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions Mol. Psychiatr. 23 2 2018 335 343
Kathagen-Buhmann A. Schulte A. Weller J. Holz M. Herold-Mende C. Glass R. Lamszus K. Glycolysis and the pentose phosphate pathway are differentially associated with the dichotomous regulation of glioblastoma cell migration versus proliferation Neuro Oncol. 18 9 2016 1219 1229 26917237
Kaushik D.K. Bhattacharya A. Mirzaei R. Rawji K.S. Ahn Y. Rho J.M. Yong V.W. Enhanced glycolytic metabolism supports transmigration of brain-infiltrating macrophages in multiple sclerosis J. Clin. Invest. 129 8 2019 3277 3292 31112527
Keating S.E. Zaiatz-Bittencourt V. Loftus R.M. Keane C. Brennan K. Finlay D.K. Gardiner C.M. Metabolic reprogramming supports IFN-gamma production by CD56bright NK cells J. Immunol. 196 6 2016 2552 2560 26873994
Kitagami T. Yamada K. Miura H. Hashimoto R. Nabeshima T. Ohta T. Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats: role of nitric oxide as a signal crossing the blood-brain barrier Brain Res. 978 1–2 2003 104 114 12834904
Kohlgruber A.C. LaMarche N.M. Lynch L. Adipose tissue at the nexus of systemic and cellular immunometabolism Semin. Immunol. 28 5 2016 431 440 27789087
Kornberg M.D. Bhargava P. Kim P.M. Putluri V. Snowman A.M. Putluri N. Calabresi P.A. Snyder S.H. Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity Science 360 6387 2018 449 453 29599194
Kramer P.A. Ravi S. Chacko B. Johnson M.S. Darley-Usmar V.M. A review of the mitochondrial and glycolytic metabolism in human platelets and leukocytes: implications for their use as bioenergetic biomarkers Redox Biol. 2 2014 206 210 24494194
Kumar A. Pyaram K. Yarosz E.L. Hong H. Lyssiotis C.A. Giri S. Chang C.H. Enhanced oxidative phosphorylation in NKT cells is essential for their survival and function Proc. Natl. Acad. Sci. U.S.A. 116 15 2019 7439 7448 30910955
Lachmandas E. Boutens L. Ratter J.M. Hijmans A. Hooiveld G.J. Joosten L.A. Rodenburg R.J. Fransen J.A. Houtkooper R.H. van Crevel R. Netea M.G. Stienstra R. Microbial stimulation of different Toll-like receptor signalling pathways induces diverse metabolic programmes in human monocytes Nat Microbiol 2 2016 16246
Lacourt T.E. Vichaya E.G. Chiu G.S. Dantzer R. Heijnen C.J. The high costs of low-grade inflammation: persistent fatigue as a consequence of reduced cellular-energy availability and non-adaptive energy expenditure Front. Behav. Neurosci. 12 2018 78 29755330
Lee M.K.S. Al-Sharea A. Shihata W.A. Bertuzzo Veiga C. Cooney O.D. Fleetwood A.J. Flynn M.C. Claeson E. Palmer C.S. Lancaster G.I. Henstridge D.C. Hamilton J.A. Murphy A.J. Glycolysis is required for LPS-induced activation and adhesion of human CD14(+)CD16(-) monocytes Front. Immunol. 10 2019 2054 31555280
Lee Y. Mansur R.B. Brietzke E. Carmona N.E. Subramaniapillai M. Pan Z. Shekotikhina M. Rosenblat J.D. Suppes T. Cosgrove V.E. Kramer N.E. McIntyre R.S. Efficacy of adjunctive infliximab vs. placebo in the treatment of anhedonia in bipolar I/II depression Brain Behav. Immun. 88 2020 631 639 32380271
Lee W. Milewski T.M. Dwortz M.F. Young R.L. Gaudet A.D. Fonken L.K. Champagne F.A. Curley J.P. Distinct immune and transcriptomic profiles in dominant versus subordinate males in mouse social hierarchies Brain Behav. Immun. 103 2022 130 144 35447300
Li J. Zhang S.X. Wang W. Cheng K. Guo H. Rao C.L. Yang D.Y. He Y. Zou D.Z. Han Y. Zhao L.B. Li P.F. Xie P. Potential antidepressant and resilience mechanism revealed by metabolomic study on peripheral blood mononuclear cells of stress resilient rats Behav. Brain Res. 320 2017 12 20 27880890
Li H. Guglielmetti C. Sei Y.J. Zilberter M. Le Page L.M. Shields L. Yang J. Nguyen K. Tiret B. Gao X. Bennett N. Lo I. Dayton T.L. Kampmann M. Huang Y. Rathmell J.C. Vander Heiden M. Chaumeil M.M. Nakamura K. Neurons require glucose uptake and glycolysis in vivo Cell Rep. 42 4 2023 112335
Liu J.J. Wei Y.B. Strawbridge R. Bao Y. Chang S. Shi L. Que J. Gadad B.S. Trivedi M.H. Kelsoe J.R. Lu L. Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis Mol. Psychiatr. 25 2 2020 339 350
Liu R. Gong Y. Xia C. Cao Y. Zhao C. Zhou M. Itaconate: a promising precursor for treatment of neuroinflammation associated depression Biomed. Pharmacother. 167 2023 115521
Lucido M.J. Bekhbat M. Goldsmith D.R. Treadway M.T. Haroon E. Felger J.C. Miller A.H. Aiding and abetting anhedonia: impact of inflammation on the brain and pharmacological implications Pharmacol. Rev. 73 3 2021 1084 1117 34285088
Lynall M.E. Turner L. Bhatti J. Cavanagh J. de Boer P. Mondelli V. Jones D. Drevets W.C. Cowen P. Harrison N.A. Pariante C.M. Pointon L. Clatworthy M.R. Bullmore E. Neuroimmunology of mood D, alzheimer's disease C. Peripheral blood cell-stratified subgroups of inflamed depression Biol. Psychiatr. 2019
Marelli-Berg F.M. Jangani M. Metabolic regulation of leukocyte motility and migration J. Leukoc. Biol. 104 2 2018 285 293 29451682
McIntyre R.S. Subramaniapillai M. Lee Y. Pan Z. Carmona N.E. Shekotikhina M. Rosenblat J.D. Brietzke E. Soczynska J.K. Cosgrove V.E. Miller S. Fischer E.G. Kramer N.E. Dunlap K. Suppes T. Mansur R.B. Efficacy of adjunctive infliximab vs placebo in the treatment of adults with bipolar I/II depression: a randomized clinical trial JAMA Psychiatr. 2019
McKim D.B. Patterson J.M. Wohleb E.S. Jarrett B.L. Reader B.F. Godbout J.P. Sheridan J.F. Sympathetic release of splenic monocytes promotes recurring anxiety following repeated social defeat Biol. Psychiatr. 79 10 2016 803 813
McKim D.B. Yin W. Wang Y. Cole S.W. Godbout J.P. Sheridan J.F. Social stress mobilizes hematopoietic stem cells to establish persistent splenic myelopoiesis Cell Rep. 25 9 2018 2552 25562 e3 30485819
McKim D.B. Weber M.D. Niraula A. Sawicki C.M. Liu X. Jarrett B.L. Ramirez-Chan K. Wang Y. Roeth R.M. Sucaldito A.D. Sobol C.G. Quan N. Sheridan J.F. Godbout J.P. Microglial recruitment of IL-1beta-producing monocytes to brain endothelium causes stress-induced anxiety Mol. Psychiatr. 23 6 2018 1421 1431
Mehta D. Raison C.L. Woolwine B.J. Haroon E. Binder E.B. Miller A.H. Felger J.C. Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression Brain Behav. Immun. 31 2013 205 215 23624296
Menard C. Pfau M.L. Hodes G.E. Kana V. Wang V.X. Bouchard S. Takahashi A. Flanigan M.E. Aleyasin H. LeClair K.B. Janssen W.G. Labonte B. Parise E.M. Lorsch Z.S. Golden S.A. Heshmati M. Tamminga C. Turecki G. Campbell M. Fayad Z.A. Tang C.Y. Merad M. Russo S.J. Social stress induces neurovascular pathology promoting depression Nat. Neurosci. 20 12 2017 1752 1760 29184215
Michl J. Ohlbaum D.J. Silverstein S.C. 2-Deoxyglucose selectively inhibits Fc and complement receptor-mediated phagocytosis in mouse peritoneal macrophages II. Dissociation of the inhibitory effects of 2-deoxyglucose on phagocytosis and ATP generation J. Exp. Med. 144 6 1976 1484 1493 1003099
Michopoulos V. Powers A. Gillespie C.F. Ressler K.J. Jovanovic T. Inflammation in fear- and anxiety-based disorders: PTSD, GAD, and beyond Neuropsychopharmacology 42 1 2017 254 270 27510423
Milaneschi Y. Lamers F. Berk M. Penninx B. Depression heterogeneity and its biological underpinnings: toward immunometabolic depression Biol. Psychiatr. 2020
Miller A.H. Haroon E. Felger J.C. Therapeutic implications of brain-immune interactions: treatment in translation Neuropsychopharmacology 42 1 2017 334 359 27555382
Mills E.L. ONeill L.A. Reprogramming mitochondrial metabolism in macrophages as an anti-inflammatory signal Eur. J. Immunol. 46 1 2016 13 21 26643360
OConnor J.C. Andre C. Wang Y. Lawson M.A. Szegedi S.S. Lestage J. Castanon N. Kelley K.W. Dantzer R. Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin J. Neurosci. 29 13 2009 4200 4209 19339614
ONeill L.A.J. Artyomov M.N. Itaconate: the poster child of metabolic reprogramming in macrophage function Nat. Rev. Immunol. 19 5 2019 273 281 30705422
ONeill L.A. Kishton R.J. Rathmell J. A guide to immunometabolism for immunologists Nat. Rev. Immunol. 16 9 2016 553 565 27396447
ORourke S.A. Neto N.G.B. Devilly E. Shanley L.C. Fitzgerald H.K. Monaghan M.G. Dunne A. Cholesterol crystals drive metabolic reprogramming and M1 macrophage polarisation in primary human macrophages Atherosclerosis 352 2022 35 45 35667162
Osimo E.F. Baxter L.J. Lewis G. Jones P.B. Khandaker G.M. Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels Psychol. Med. 49 12 2019 1958 1970 31258105
PalssonMcDermott E.M. ONeill L.A.J. Targeting immunometabolism as an anti-inflammatory strategy Cell Res. 30 4 2020 300 314 32132672
Palsson-McDermott E.M. Curtis A.M. Goel G. Lauterbach M.A. Sheedy F.J. Gleeson L.E. van den Bosch M.W. Quinn S.R. Domingo-Fernandez R. Johnston D.G. Jiang J.K. Israelsen W.J. Keane J. Thomas C. Clish C. Vander Heiden M. Xavier R.J. O'Neill L.A. Pyruvate kinase M2 regulates Hif-1alpha activity and IL-1beta induction and is a critical determinant of the warburg effect in LPS-activated macrophages Cell Metabol. 21 1 2015 65 80
Passos I.C. Vasconcelos-Moreno M.P. Costa L.G. Kunz M. Brietzke E. Quevedo J. Salum G. Magalhães P.V. Kapczinski F. Kauer-Sant'Anna M. Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression Lancet Psychiatr. 2 11 2015 1002 1012
Pavlou S. Wang L. Xu H. Chen M. Higher phagocytic activity of thioglycollate-elicited peritoneal macrophages is related to metabolic status of the cells J. Inflamm. 14 2017 4
Peace C.G. ONeill L.A. The role of itaconate in host defense and inflammation J. Clin. Invest. 132 2 2022
Pearce E.L. Pearce E.J. Metabolic pathways in immune cell activation and quiescence Immunity 38 4 2013 633 643 23601682
Pearson T.A. Mensah G.A. Alexander R.W. Anderson J.L. Cannon R.O. 3rd Criqui M. Fadl Y.Y. Fortmann S.P. Hong Y. Myers G.L. Rifai N. Smith S.C. Jr. Taubert K. Tracy R.P. Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association Circulation 107 3 2003 499 511 12551878
Raez L.E. Papadopoulos K. Ricart A.D. Chiorean E.G. Dipaola R.S. Stein M.N. Rocha Lima C.M. Schlesselman J.J. Tolba K. Langmuir V.K. Kroll S. Jung D.T. Kurtoglu M. Rosenblatt J. Lampidis T.J. A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors Cancer Chemother. Pharmacol. 71 2 2013 523 530 23228990
Raison C.L. Rutherford R.E. Woolwine B.J. Shuo C. Schettler P. Drake D.F. Haroon E. Miller A.H. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers JAMA Psychiatr. 70 1 2013 31 41
Ratter J.M. van Heck J.I.P. Rooijackers H.M.M. Jansen H.J. van Poppel P.C.M. Tack C.J. Stienstra R. Insulin acutely activates metabolism of primary human monocytes and promotes a proinflammatory phenotype J. Leukoc. Biol. 2021
Real F. Zhu A. Huang B. Belmellat A. Sennepin A. Vogl T. Ransy C. Revol M. Arrigucci R. Lombes A. Roth J. Gennaro M.L. Bouillaud F. Cristofari S. Bomsel M. S100A8-mediated metabolic adaptation controls HIV-1 persistence in macrophages in vivo Nat. Commun. 13 1 2022 5956 36220814
Rosenblat J.D. McIntyre R.S. Efficacy and tolerability of minocycline for depression: a systematic review and meta-analysis of clinical trials J. Affect. Disord. 227 2018 219 225 29102836
Saare M. Tserel L. Haljasmagi L. Taalberg E. Peet N. Eimre M. Vetik R. Kingo K. Saks K. Tamm R. Milani L. Kisand K. Peterson P. Monocytes present age-related changes in phospholipid concentration and decreased energy metabolism Aging Cell 19 4 2020 e13127
Salvadore G. Nash A. Bleys C. Hsu B. Saad Z. Gause A. Moyer J. Xi L. Manji H. Van Nueten L. Drevets W. A double-blind, placebo-controlled, multicenter study of sirukumab as adjunctive treatment to a monoaminergic antidepressant in adults with major depressive disorder, in ACNP 57th annual meeting: poster session II, hollywood, FL Neuropsychopharmacology 43 1 2018 228 382 29192653
Sawicki C.M. McKim D.B. Wohleb E.S. Jarrett B.L. Reader B.F. Norden D.M. Godbout J.P. Sheridan J.F. Social defeat promotes a reactive endothelium in a brain region-dependent manner with increased expression of key adhesion molecules, selectins and chemokines associated with the recruitment of myeloid cells to the brain Neuroscience 302 2015 151 164 25445193
Schioppa T. Uranchimeg B. Saccani A. Biswas S.K. Doni A. Rapisarda A. Bernasconi S. Saccani S. Nebuloni M. Vago L. Mantovani A. Melillo G. Sica A. Regulation of the chemokine receptor CXCR4 by hypoxia J. Exp. Med. 198 9 2003 1391 1402 14597738
Schmidl C. Renner K. Peter K. Eder R. Lassmann T. Balwierz P.J. Itoh M. Nagao-Sato S. Kawaji H. Carninci P. Suzuki H. Hayashizaki Y. Andreesen R. Hume D.A. Hoffmann P. Forrest A.R. Kreutz M.P. Edinger M. Rehli M. consortium F. Transcription and enhancer profiling in human monocyte subsets Blood 123 17 2014 e90 e99 24671955
Schmidt S. Stautner C. Vu D.T. Heinz A. Regensburger M. Karayel O. Trumbach D. Artati A. Kaltenhauser S. Nassef M.Z. Hembach S. Steinert L. Winner B. Jurgen W. Jastroch M. Luecken M.D. Theis F.J. Westmeyer G.G. Adamski J. Mann M. Hiller K. Giesert F. Vogt Weisenhorn D.M. Wurst W. A reversible state of hypometabolism in a human cellular model of sporadic Parkinson's disease Nat. Commun. 14 1 2023 7674 37996418
Semba H. Takeda N. Isagawa T. Sugiura Y. Honda K. Wake M. Miyazawa H. Yamaguchi Y. Miura M. Jenkins D.M. Choi H. Kim J.W. Asagiri M. Cowburn A.S. Abe H. Soma K. Koyama K. Katoh M. Sayama K. Goda N. Johnson R.S. Manabe I. Nagai R. Komuro I. HIF-1alpha-PDK1 axis-induced active glycolysis plays an essential role in macrophage migratory capacity Nat. Commun. 7 2016 11635
Seth P. Csizmadia E. Hedblom A. Vuerich M. Xie H. Li M. Longhi M.S. Wegiel B. Deletion of lactate dehydrogenase-A in myeloid cells triggers antitumor immunity Cancer Res. 77 13 2017 3632 3643 28446465
Shannon B.J. Vaishnavi S.N. Vlassenko A.G. Shimony J.S. Rutlin J. Raichle M.E. Brain aerobic glycolysis and motor adaptation learning Proc. Natl. Acad. Sci. U.S.A. 113 26 2016 E3782 E3791 27217563
Shibata T. Yamagata H. Uchida S. Otsuki K. Hobara T. Higuchi F. Abe N. Watanabe Y. The alteration of hypoxia inducible factor-1 (HIF-1) and its target genes in mood disorder patients Prog. Neuro-Psychopharmacol. Biol. Psychiatry 43 2013 222 229
Shytaj I.L. Procopio F.A. Tarek M. Carlon-Andres I. Tang H.Y. Goldman A.R. Munshi M. Kumar Pal V. Forcato M. Sreeram S. Leskov K. Ye F. Lucic B. Cruz N. Ndhlovu L.C. Bicciato S. Padilla-Parra S. Diaz R.S. Singh A. Lusic M. Karn J. Alvarez-Carbonell D. Savarino A. Glycolysis downregulation is a hallmark of HIV-1 latency and sensitizes infected cells to oxidative stress EMBO Mol. Med. 13 8 2021 e13901
Song S. Yu L. Hasan M.N. Paruchuri S.S. Mullett S.J. Sullivan M.L.G. Fiesler V.M. Young C.B. Stolz D.B. Wendell S.G. Sun D. Elevated microglial oxidative phosphorylation and phagocytosis stimulate post-stroke brain remodeling and cognitive function recovery in mice Commun. Biol. 5 1 2022 35 35017668
Stark J.L. Avitsur R. Padgett D.A. Campbell K.A. Beck F.M. Sheridan J.F. Social stress induces glucocorticoid resistance in macrophages Am. J. Physiol. Regul. Integr. Comp. Physiol. 280 6 2001 R1799 R1805 11353685
Stein M. Lin H. Jeyamohan C. Dvorzhinski D. Gounder M. Bray K. Eddy S. Goodin S. White E. Dipaola R.S. Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies Prostate 70 13 2010 1388 1394 20687211
Stifel U. Wolfschmitt E.M. Vogt J. Wachter U. Vettorazzi S. Tews D. Hogg M. Zink F. Koll N.M. Winning S. Mounier R. Chazaud B. Radermacher P. Fischer-Posovszky P. Caratti G. Tuckermann J. Glucocorticoids coordinate macrophage metabolism through the regulation of the tricarboxylic acid cycle Mol. Metabol. 57 2022 101424
Strawbridge R. Arnone D. Danese A. Papadopoulos A. Herane Vives A. Cleare A.J. Inflammation and clinical response to treatment in depression: a meta-analysis Eur. Neuropsychopharmacol 25 10 2015 1532 1543 26169573
Sturm G. Karan K.R. Monzel A.S. Santhanam B. Taivassalo T. Bris C. Ware S.A. Cross M. Towheed A. Higgins-Chen A. McManus M.J. Cardenas A. Lin J. Epel E.S. Rahman S. Vissing J. Grassi B. Levine M. Horvath S. Haller R.G. Lenaers G. Wallace D.C. St-Onge M.P. Tavazoie S. Procaccio V. Kaufman B.A. Seifert E.L. Hirano M. Picard M. OxPhos defects cause hypermetabolism and reduce lifespan in cells and in patients with mitochondrial diseases Commun. Biol. 6 1 2023 22 36635485
Szwed A. Kim E. Jacinto E. Regulation and metabolic functions of mTORC1 and mTORC2 Physiol. Rev. 101 3 2021 1371 1426 33599151
Tannahill G.M. Curtis A.M. Adamik J. Palsson-McDermott E.M. McGettrick A.F. Goel G. Frezza C. Bernard N.J. Kelly B. Foley N.H. Zheng L. Gardet A. Tong Z. Jany S.S. Corr S.C. Haneklaus M. Caffrey B.E. Pierce K. Walmsley S. Beasley F.C. Cummins E. Nizet V. Whyte M. Taylor C.T. Lin H. Masters S.L. Gottlieb E. Kelly V.P. Clish C. Auron P.E. Xavier R.J. O'Neill L.A. Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha Nature 496 7444 2013 238 242 23535595
Thiem K. van Dierendonck X. Janssen A.W.M. Boogaard J.P. Riksen N.P. Tack C.J. Stienstra R. A high glycemic burden relates to functional and metabolic alterations of human monocytes in patients with type 1 diabetes Diabetes 69 12 2020 2735 2746 32978233
Torres-Platas S.G. Cruceanu C. Chen G.G. Turecki G. Mechawar N. Evidence for increased microglial priming and macrophage recruitment in the dorsal anterior cingulate white matter of depressed suicides Brain Behav. Immun. 42 2014 50 59 24858659
Treadway M.T. Zald D.H. Reconsidering anhedonia in depression: lessons from translational neuroscience Neurosci. Biobehav. Rev. 35 3 2011 537 555 20603146
Treadway M.T. Buckholtz J.W. Cowan R.L. Woodward N.D. Li R. Ansari M.S. Baldwin R.M. Schwartzman A.N. Kessler R.M. Zald D.H. Dopaminergic mechanisms of individual differences in human effort-based decision-making J. Neurosci. 32 18 2012 6170 6176 22553023
Tucci G. Garufi C. Pacella I. Zagaglioni M. Pinzon Grimaldos A. Ceccarelli F. Conti F. Spinelli F.R. Piconese S. Baricitinib therapy response in rheumatoid arthritis patients associates to STAT1 phosphorylation in monocytes Front. Immunol. 13 2022 932240
Vanderbeke L. Van Mol P. Van Herck Y. De Smet F. Humblet-Baron S. Martinod K. Antoranz A. Arijs I. Boeckx B. Bosisio F.M. Casaer M. Dauwe D. De Wever W. Dooms C. Dreesen E. Emmaneel A. Filtjens J. Gouwy M. Gunst J. Hermans G. Jansen S. Lagrou K. Liston A. Lorent N. Meersseman P. Mercier T. Neyts J. Odent J. Panovska D. Penttila P.A. Pollet E. Proost P. Qian J. Quintelier K. Raes J. Rex S. Saeys Y. Sprooten J. Tejpar S. Testelmans D. Thevissen K. Van Buyten T. Vandenhaute J. Van Gassen S. Velasquez Pereira L.C. Vos R. Weynand B. Wilmer A. Yserbyt J. Garg A.D. Matthys P. Wouters C. Lambrechts D. Wauters E. Wauters J. Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity Nat. Commun. 12 1 2021 4117 34226537
Veenhuis R.T. Williams D.W. Shirk E.N. Monteiro Abreu C. Ferreira E.A. Coughlin J.M. Brown T.T. Maki P.M. Anastos K. Berman J.W. Clements J.E. Rubin L.H. Higher circulating intermediate monocytes are associated with cognitive function in women with HIV JCI Insight 2021
Viola A. Munari F. Sanchez-Rodriguez R. Scolaro T. Castegna A. The metabolic signature of macrophage responses Front. Immunol. 10 2019 1462 31333642
Vrieling F. van Dierendonck X. Jaeger M. Janssen A.W.M. Hijmans A. Netea M.G. Tack C.J. Stienstra R. Glycolytic activity in human immune cells: inter-individual variation and functional implications during health and diabetes Immunometabolism 4 4 2022 e00008
Walker A.K. Budac D.P. Bisulco S. Lee A.W. Smith R.A. Beenders B. Kelley K.W. Dantzer R. NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice Neuropsychopharmacology 38 9 2013 1609 1616 23511700
Wang A. Luan H.H. Medzhitov R. An evolutionary perspective on immunometabolism Science 363 6423 2019
Wang Y. Stancliffe E. Fowle-Grider R. Wang R. Wang C. Schwaiger-Haber M. Shriver L.P. Patti G.J. Saturation of the mitochondrial NADH shuttles drives aerobic glycolysis in proliferating cells Mol. Cell 82 17 2022 3270 32783 e9 35973426
Wang C. Cheng Y. Li B. Qiu X. Hu H. Zhang X. Lu Z. Zheng F. Transcriptional characteristics and functional validation of three monocyte subsets during aging Immun. Ageing 20 1 2023 50 37759225
Watson K.T. Simard J.F. Henderson V.W. Nutkiewicz L. Lamers F. Nasca C. Rasgon N. Penninx B. Incident major depressive disorder predicted by three measures of insulin resistance: a Dutch cohort study Am. J. Psychiatr. 178 10 2021 914 920 34551583
Wculek S.K. Dunphy G. Heras-Murillo I. Mastrangelo A. Sancho D. Metabolism of tissue macrophages in homeostasis and pathology Cell. Mol. Immunol. 19 3 2022 384 408 34876704
Williams D.W. Byrd D. Rubin L.H. Anastos K. Morgello S. Berman J.W. CCR2 on CD14(+)CD16(+) monocytes is a biomarker of HIV-associated neurocognitive disorders Neurol Neuroimmunol Neuroinflamm 1 3 2014 e36
Wohleb E.S. Powell N.D. Godbout J.P. Sheridan J.F. Stress-induced recruitment of bone marrow-derived monocytes to the brain promotes anxiety-like behavior J. Neurosci. 33 34 2013 13820 13833 23966702
Wohleb E.S. McKim D.B. Shea D.T. Powell N.D. Tarr A.J. Sheridan J.F. Godbout J.P. Re-establishment of anxiety in stress-sensitized mice is caused by monocyte trafficking from the spleen to the brain Biol. Psychiatr. 75 12 2014 970 981
Wolfe H. Mela V. Minogue A.M. Miller A.M. McGuigan C. Williams L. Lohan D. Lawlor B.A. Lynch M.A. Monocytes exposed to plasma from patients with Alzheimer's disease undergo metabolic reprogramming Neurosci. Res. 148 2019 54 60 30641113
Xie M. Yu Y. Kang R. Zhu S. Yang L. Zeng L. Sun X. Yang M. Billiar T.R. Wang H. Cao L. Jiang J. Tang D. PKM2-dependent glycolysis promotes NLRP3 and AIM2 inflammasome activation Nat. Commun. 7 2016 13280
Yang J.J. Wang N. Yang C. Shi J.Y. Yu H.Y. Hashimoto K. Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression Biol. Psychiatr. 77 3 2015 e19 e20
Yao C.-H. Wang R. Wang Y. Kung C.-P. Weber J.D. Patti G.J. Mitochondrial fusion supports increased oxidative phosphorylation during cell proliferation Elife 8 2019
Yohn S.E. Arif Y. Haley A. Tripodi G. Baqi Y. Muller C.E. Miguel N.S. Correa M. Salamone J.D. Effort-related motivational effects of the pro-inflammatory cytokine interleukin-6: pharmacological and neurochemical characterization Psychopharmacology (Berl) 233 19–20 2016 3575 3586 27497935
Zhang R. Li R. Liu Y. Li L. Tang Y. The glycolytic enzyme PFKFB3 controls TNF-alpha-induced endothelial proinflammatory responses Inflammation 42 1 2019 146 155 30171427
